Oculinea, Inc. Enters into Research Agreement with Trican Biotechnology Pipeline
September 25, 2025
Oculinea, Inc. and Trican Biotechnology based in San Francisco, Ca, and New Taipei City, Taiwan on July 1st, 2025 jointly announced a research collaboration and exclusive option and license agreement to develop a novel ophthalmology implant using antibodies from Trican.
The asset under evaluation is a bispecific antibody targeting overexpressed drivers in retinal diseases. Under the terms of the agreed-upon collaboration, Oculinea will be responsible for research and development of drug-device products incorporating this antibody. Trican will support bispecific antibody generation.
Congratulations to Robert Bhisitkul, MD PhD, Professor of Ophthalmology, UCSF and cofounder of Oculinea.